Fundraising Fox
/Companies
Sign in

MBF Therapeutics

Ambler, US · Delaware corporation

Find your way into MBF Therapeutics

Sign up to see every warm intro you have to MBF Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the MBF Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

MBF Therapeutics (MBFT) is an animal health biotechnology company developing veterinary vaccines through its T-Max platform, which combines full-length natural antigen screening, deep T-cell and B-cell immune profiling, and calcium phosphate nanoparticle delivery (CaptaVax). The company structures the immunological data from its in vitro and in vivo studies for machine learning, with the aim of training predictive immunology models; it also has a human health spinout, TeraVax Biotech.

Biotech

Founders & leadership

LH
Lorraine H. Keller, PhDCoFounder & CSO
TTThomas Tillett
Thomas TillettCoFounder & CEOThomas Tillett previously served as President and CEO of RheoGene and, following its acquisition, as a Division President at Intrexon Corporation. Earlier in his career he held commercial roles at Rohm and Haas, including Business Director for Biotechnology and Director of Marketing for Europe, and he later founded TeraVax Biotech and serves as Executive Director of Sustained Acts.

Board

CM
Christopher M. CashmanBoard director

Reported raises · per SEC filings

Form D private placements

$2.6M disclosed across 4 rounds · 2016–2023

▶$105KraisedJan 2024 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Dhiren ThakkerDirector
  • Joseph ConnorDirector
  • Aris PersidisDirector
  • Lorraine KellerExecutive Officer
  • Thomas TillettExecutive Officer, Director
  • Christopher CashmanDirector
Offering amount
$500K
Amount sold
$105K
First sale
Dec 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$814.3KraisedSep 2021 · 21 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Christopher M. CashmanDirector
  • Aris PersidisDirector
  • Dhiren ThakkerDirector
  • Thomas TillettExecutive Officer, Director
  • Chris BungeDirector
Offering amount
$3M
Amount sold
$814.3K
Proceeds to insiders
$75K
First sale
Aug 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$605KraisedMay 2019 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Christopher M. CashmanDirector
  • Thomas TillettExecutive Officer, Director
  • Chris BungeDirector
Offering amount
$2M
Amount sold
$605K
First sale
Oct 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.1MraisedNov 2016 · 14 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Christopher M. CashmanDirector
  • Thomas TillettExecutive Officer, Director
Offering amount
$1.1M
Amount sold
$1.1M
First sale
Nov 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 2

Soufflé TherapeuticsSoufflé Therapeutics develops nucleic acid medicines that precisely target and deliver genetic therapeutics to specific cell types to treat disease. The company focuses on creating potent, precise medicines for patients across various disease areas through advanced delivery platforms.
Bambusa TherapeuticsBambusa Therapeutics develops bispecific antibodies for immunological and inflammatory (I&I) disorders, using antibody engineering to target multiple I&I indications. The clinical-stage biotech company serves patients across a range of I&I diseases.

Companies working in the same space as MBF Therapeutics.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken
AgencyPhaseYearAmount
National Science FoundationPhase ISTTR2022$256K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does MBF Therapeutics do?
MBF Therapeutics (MBFT) is an animal health biotechnology company developing veterinary vaccines through its T-Max platform, which combines full-length natural antigen screening, deep T-cell and B-cell immune profiling, and calcium phosphate nanoparticle delivery (CaptaVax). The company structures the immunological data from its in vitro and in vivo studies for machine learning, with the aim of training predictive immunology models; it also has a human health spinout, TeraVax Biotech.
Who founded MBF Therapeutics?
MBF Therapeutics was founded by Lorraine H. Keller, PhD.
How much funding has MBF Therapeutics raised?
MBF Therapeutics has disclosed $2.6M raised across 4 rounds.
Where is MBF Therapeutics headquartered?
MBF Therapeutics is headquartered in Ambler, US.